A magnesium alloy and a preparation method and application thereof

Abstract

This invention provides a magnesium alloy, its preparation method, and its applications. The magnesium alloy comprises a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body. A protein carrier is adsorbed on the surface of the peroxide coating, and a NO donor is loaded onto the surface of the protein carrier. The magnesium alloy body can generate hydrogen gas in situ within the acidic tumor microenvironment, downregulating the expression of heat shock proteins in tumor cells, making tumor cells sensitive to temperature, and killing tumor cells under a low-intensity alternating magnetic field. Simultaneously, the peroxide coating stimulates the release of NO from the NO donor in the acidic tumor microenvironment, while the magnesium alloy body promotes the production of heat-activated oxygen substances inside cancer cells, which further react with NO to produce more toxic reactive nitrogen substances, achieving further killing of tumor cells.

Description

Technical Field

[0001] This invention belongs to the field of magnesium alloy preparation technology, specifically relating to a magnesium alloy, its preparation method, and its application. Background Technology

[0002] Currently, surgical resection remains the primary means of treating tumors in clinical practice. However, the edges of many invasive tumors are difficult to distinguish during surgery, and residual tumor tissue after surgery leads to a significant risk of postoperative recurrence. Postoperative radiotherapy and chemotherapy are still the main methods for eliminating residual tumor tissue in clinical practice, but due to their high systemic toxicity and low sensitivity, the treatment effect remains unsatisfactory.

[0003] Currently, among the numerous treatment methods for preventing postoperative tumor recurrence, magnetothermal therapy, which utilizes the heat generated by magnetic nanoparticles under an alternating magnetic field to eliminate tumors, is gaining increasing attention due to its advantages such as being non-invasive, safe, and having unlimited penetration depth. For example, CN 114949266 A discloses a magnetic nanoprobe for breast cancer responsive multimodal imaging and diagnosis, which possesses magnetothermal heating characteristics and controllable drug release; CN 115317606 B discloses a magnetic nanodroplet that increases the penetration of solid tumors and has magnetothermal-sensitized immunotherapy efficacy. This magnetic nanodroplet has a certain degree of penetration into solid tumors and possesses the characteristic of magnetothermal-induced thermal ablation of tumor cells. However, magnetic nanoparticles, as magnetothermal agents, inevitably accumulate in normal tissues during systemic blood circulation, leading to thermal damage to normal tissues. In addition, high temperatures promote the expression of heat shock proteins in tumor cells, which repair damaged proteins within cancer cells, making tumor cells insensitive to high temperatures. Therefore, higher temperatures are generally required to cause thermal damage to tumor cells.

[0004] Magnesium alloys, due to their inherent eddy current heating properties and good degradation resistance, hold promise as a potential magnetothermal therapy agent. For example, CN111449830A discloses the application of implantable metals as precise and efficient magnetothermal therapy agents for tumors. This patent proposes utilizing the heat energy generated by the eddy current heating effect of implantable metals under an alternating magnetic field to achieve magnetothermal therapy for tumors. The alternating magnetic field strength ranges from 0.1 to 10 × 10⁻⁶. 9 A·m -1 ·s -1CN116254445A discloses that Mg-Al-Ca ternary magnesium alloys can be used as anti-tumor implant materials or magnetothermal therapy media. However, simply applying metal implants to postoperative wounds, such as magnesium alloys, under an alternating magnetic field can generate high temperatures that can kill tumor cells, but this can further cause thermal damage to a large area of ​​surrounding normal tissue, leading to certain side effects and hindering postoperative recovery. Therefore, there is an urgent need to explore a method that can safely and effectively eliminate residual tumor tissue after surgery and continuously inhibit the in situ recurrence of tumor tissue under a low-intensity alternating magnetic field. Summary of the Invention

[0005] In view of this, the object of the present invention is to provide a magnesium alloy, its preparation method, and its application. The magnesium alloy can be used under a low-intensity alternating magnetic field (0.1 × 10⁻⁶). 8 ~0.9×10 8 A·m -1 ·s -1 This method uses relatively gentle temperatures to perform thermotherapy to kill tumor cells, thereby further protecting the surrounding normal tissues.

[0006] To achieve this objective, the present invention adopts the following technical solution:

[0007] In a first aspect, the present invention provides a magnesium alloy, comprising a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body.

[0008] The peroxide coating surface is adsorbed with a protein carrier, and the protein carrier surface is loaded with a NO donor.

[0009] Preferably, the peroxide coating includes any one or more of a magnesium peroxide coating, a zinc peroxide coating, a calcium peroxide coating, or a strontium peroxide coating.

[0010] Preferably, the protein carrier is selected from any one or more of bovine serum albumin, human serum albumin, rabbit serum albumin, or ovalbumin.

[0011] Preferably, the NO donor is selected from any one or more of poly-L-arginine hydrochloride, poly-L-arginine, or L-arginine.

[0012] Preferably, the magnesium alloy includes Mg and any one or more of Zn, Ca, Y, Nd, Gd, Sm or Zr.

[0013] Secondly, the present invention provides a method for preparing the above-mentioned magnesium alloy, comprising the following steps:

[0014] A magnesium alloy substrate coated with an oxide layer is mixed with a buffer solution of a protein carrier and reacted. The resulting product is then mixed with a buffer solution of a NO donor and reacted to obtain the magnesium alloy.

[0015] Preferably, the buffer solutions for the protein carrier and the NO donor are neutral in pH.

[0016] Preferably, the magnesium alloy body with an oxide coating is prepared by in-situ growth or surface deposition.

[0017] Thirdly, the present invention provides a metal implant that inhibits tumor growth or inhibits local tumor recurrence, comprising the aforementioned magnesium alloy.

[0018] Preferably, the metal implant (i.e., magnesium alloy) is placed in the tumor cell wound after surgery, and an alternating magnetic field is applied to stimulate it.

[0019] Preferably, the strength of the alternating magnetic field is 0.1 × 10⁻⁶. 8 ~0.9×10 8 A·m -1 ·s -1 .

[0020] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0021] This invention provides a magnesium alloy comprising a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body. The peroxide coating surface is adsorbed with a protein carrier, and the protein carrier surface is loaded with a NO donor. The magnesium alloy body of this invention can generate hydrogen gas in situ within the acidic microenvironment of tumor cells, downregulating the expression of heat shock proteins in tumor cells, making the tumor cells sensitive to temperature, and allowing them to survive under low-intensity alternating magnetic fields (0.1 × 10⁻⁶). 8 ~0.9×10 8 A·m -1 ·s -1 This invention utilizes a relatively gentle temperature to perform thermotherapy to kill tumor cells, achieving a gentle magnetothermal therapy while further protecting surrounding normal tissues. Simultaneously, the peroxide coating decomposes within the acidic tumor microenvironment to produce H2O2. H2O2 stimulates the release of NO gas molecules from NO donors. Since gentle magnetothermal therapy promotes the production of heat-activated oxygen substances within cancer cells, these reactive oxygen substances further react with the released NO gas molecules to produce more toxic reactive nitrogen substances, thereby achieving further damage to tumor cells. Therefore, the magnesium alloy provided by this invention can achieve synergistic treatment of gentle magnetothermal therapy and gas therapy, further thoroughly eliminating residual tumor cells.

[0022] It is important to note that the magnesium alloy provided by this invention can be implanted in situ within the tumor cell wound after surgery, without circulating through the bloodstream and without accumulating in normal tissue. Furthermore, the excitation source is a low-intensity alternating magnetic field, allowing for unrestricted penetration depth and a wider range of therapeutic applications. While reducing the impact of magnetothermal therapy on surrounding normal cells, it significantly enhances the killing effect of the magnesium alloy on residual tumor tissue. Moreover, the magnesium alloy degrades slowly, making it suitable as an adjunct therapy material after tumor resection and demonstrating great potential in the sustained inhibition of local tumor recurrence. Attached Figure Description

[0023] Figure 1 This is a scanning electron microscope image of the surface-modified magnesium alloy prepared in Example 1 of the present invention;

[0024] Figure 2 The X-ray diffraction pattern of the surface-modified magnesium alloy prepared in Example 1 of this invention;

[0025] Figure 3 Thermogravimetric analysis spectrum of the surface-modified magnesium alloy prepared in Example 1 of this invention;

[0026] Figure 4 This is a diagram illustrating the killing effect of the surface-modified magnesium alloy prepared in Example 1 of the present invention on tumor cells.

[0027] Figure 5 This is a scanning electron microscope image of the magnesium alloy with a zinc oxide coating prepared in Example 2 of the present invention.

[0028] Figure 6 The image shows the X-ray energy dispersive spectrum of the magnesium alloy with a zinc oxide coating prepared in Example 2 of this invention. Detailed Implementation

[0029] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.

[0030] In the existing technology, when magnesium alloys are used as a magnetic therapy medium, the high temperatures generated under an alternating magnetic field, which can kill tumor cells, can further cause thermal damage to a large area of ​​surrounding normal tissue, hindering the patient's postoperative recovery. The present invention provides a magnesium alloy comprising a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body. The surface of the peroxide coating is adsorbed with a protein carrier, and the surface of the protein carrier is loaded with a NO donor.

[0031] This invention does not impose any particular restriction on the source of the magnesium alloy matrix; it can be a commercially available magnesium alloy matrix containing non-toxic and harmless elements. The magnesium alloy matrix preferably includes Mg and any one or more of Zn, Ca, Y, Nd, Gd, Sm, or Zr. Generally, the content of metallic Zn in the magnesium alloy matrix ranges from 0.1 to 80 wt%; the content of Ca ranges from 0.1 to 10 wt%; the content of Y ranges from 0.1 to 20 wt%; the content of Nd ranges from 0.1 to 20 wt%; the content of Gd ranges from 0.1 to 20 wt%; the content of Sm ranges from 0.1 to 20 wt%; and the content of Zr ranges from 0.1 to 2 wt%.

[0032] In this invention, the peroxide coating preferably includes one or more of magnesium peroxide, zinc peroxide, calcium peroxide, or strontium peroxide, more preferably magnesium peroxide. In this invention, the protein carrier is adsorbed onto the surface of the peroxide coating through coordination, and the NO donor is adsorbed onto the surface of the protein carrier through electrostatic adsorption. For example, when the NO donor is selected from one or more of poly-L-arginine hydrochloride, poly-L-arginine, or L-arginine, the protein carrier can be selected from one or more of bovine serum albumin, human serum albumin, rabbit serum albumin, or ovalbumin. In some embodiments of this invention, the NO donor is preferably poly-L-arginine hydrochloride, and the protein carrier is preferably bovine serum albumin.

[0033] The magnesium alloy provided by this invention includes a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body. A protein carrier is adsorbed on the surface of the peroxide coating, and a NO donor is loaded on the surface of the protein carrier. The magnesium alloy body can generate hydrogen gas in situ within the acidic microenvironment of a tumor, downregulating the expression of heat shock proteins in tumor cells, making the tumor cells sensitive to temperature, and allowing them to survive under a low-intensity alternating magnetic field (0.1 × 10⁻⁶). 8 ~0.9×10 8 A·m -1 ·s -1 This invention utilizes a relatively gentle temperature to perform thermotherapy to kill tumor cells, achieving a gentle magnetothermal therapy while further protecting surrounding normal tissues. Simultaneously, the peroxide coating decomposes within the acidic tumor microenvironment to produce H2O2. H2O2 stimulates the release of NO gas molecules from NO donors. Since gentle magnetothermal therapy promotes the production of heat-activated oxygen substances within cancer cells, these reactive oxygen substances further react with the released NO gas molecules to produce more toxic reactive nitrogen substances, thereby achieving further damage to tumor cells. Therefore, the magnesium alloy provided by this invention can achieve synergistic treatment of gentle magnetothermal therapy and gas therapy, further thoroughly eliminating residual tumor cells.

[0034] The present invention also provides a method for preparing the above-mentioned magnesium alloy, comprising the following steps:

[0035] A magnesium alloy substrate coated with an oxide layer is mixed with a buffer solution of a protein carrier and reacted. The resulting product is then mixed with a buffer solution of a NO donor and reacted to obtain the magnesium alloy.

[0036] According to this invention, a magnesium alloy substrate coated with an oxide layer is first mixed and reacted with a buffer solution of a protein-based carrier. In this invention, the magnesium alloy substrate coated with an oxide layer requires different preparation methods depending on the type of oxide coating. Generally, it can be prepared by in-situ growth or surface deposition.

[0037] In some embodiments of the present invention, when the peroxide coating is a magnesium peroxide coating, it is preferable to use an in-situ growth method to obtain a magnesium alloy body with a magnesium peroxide coating on its surface, specifically including the following steps:

[0038] Magnesium alloy body is immersed in saturated sodium bicarbonate solution and reacted for 5–15 hours, preferably 12 hours, to obtain magnesium alloy a; magnesium alloy a is calcined at 300–600°C, preferably 500°C, for 2–6 hours, preferably 3 hours, to obtain magnesium alloy b; magnesium alloy b is immersed in hydrogen peroxide solution and reacted for 5–15 hours, preferably 12 hours, to obtain magnesium alloy body with a magnesium peroxide coating grown on the surface. The calcination is preferably carried out in a muffle furnace.

[0039] In some embodiments of the present invention, when the peroxide coating is a zinc peroxide coating, a calcium peroxide coating, or a strontium peroxide coating, a surface deposition method is preferred. Taking the magnesium alloy body with a zinc peroxide coating as an example, the present invention specifically includes the following steps:

[0040] The magnesium alloy body is immersed in a solution of polyvinylpyrrolidone or polyvinyl alcohol for deposition and adsorption for 0.5 to 3 hours, preferably 2 hours. The obtained product is then immersed in an aqueous solution of zinc acetate and mixed by shaking in a shaker for 2 to 5 hours, preferably 4 hours. Hydrogen peroxide solution is then added to the obtained solution, preferably 3 mL of 30 wt% hydrogen peroxide solution, and the solution is placed on a heating plate at 200 to 500°C, preferably 300°C, and heated for 5 to 20 minutes, preferably 15 minutes, to obtain a magnesium alloy body with a zinc peroxide coating grown on its surface.

[0041] It should be noted that when the peroxide coating is a calcium peroxide coating or a strontium peroxide coating, the magnesium alloy body with a surface grown with a calcium peroxide coating or a strontium peroxide coating can be prepared by referring to the above method, which will not be elaborated here.

[0042] After obtaining a magnesium alloy body with a peroxide coating, the present invention preferably mixes and reacts it with a buffer solution of a protein carrier. The buffer solution of the protein carrier is preferably a phosphate buffer solution of the protein carrier, and its acidity or alkalinity is preferably neutral to avoid degradation of the peroxide coating. In some embodiments of the present invention, it is preferred to mix the magnesium alloy body with the peroxide coating with a buffer solution of 1.0–2.0 g / L, preferably 1.6 g / L, of the protein carrier, and react at room temperature for 8–20 h, preferably 12 h, to obtain a magnesium alloy body with a peroxide coating grown on the surface and loaded with a protein carrier.

[0043] Then, the magnesium alloy substrate with a peroxide coating grown on its surface and loaded with a protein carrier is mixed with a buffer solution containing a NO donor and reacted to obtain a magnesium alloy. The buffer solution containing the NO donor is preferably a phosphate buffer solution containing a NO donor, and its acidity or alkalinity is preferably neutral, to avoid degradation of the peroxide coating. In some embodiments of the present invention, it is preferable to mix the magnesium alloy substrate with a peroxide coating grown on its surface and loaded with a protein carrier with a buffer solution containing 0.3–1.0 g / L, preferably 0.6 g / L, of a NO donor, and react at room temperature for 8–20 h, preferably 12 h, to obtain the magnesium alloy.

[0044] In this invention, the above-mentioned room temperature refers to a temperature of "20 to 30°C", preferably 25°C.

[0045] The method for preparing the magnesium alloy provided by this invention is simple, convenient, and easy to implement.

[0046] The present invention also provides a metal implant for inhibiting tumor growth or inhibiting local tumor recurrence, wherein the metal implant is a magnesium alloy involved in the above technical solution.

[0047] In this invention, the application of the metal implant, namely magnesium alloy, is simple and can be carried out by the following steps:

[0048] The metal implant, namely magnesium alloy, is placed in the tumor cell wound after surgery, and an alternating magnetic field is applied to stimulate it.

[0049] In this invention, the intensity of the alternating magnetic field is low, specifically 0.1 × 10⁻⁶. 8 ~0.9×10 8 A·m -1 ·s -1 .

[0050] In summary, the magnesium alloy provided by this invention can be implanted in situ within the tumor cell wound after surgery, without circulating through the bloodstream and without accumulating in normal tissue. Furthermore, the excitation source is a low-intensity alternating magnetic field, allowing for unlimited penetration depth and a wider range of therapeutic applications. While reducing the impact of magnetothermal therapy on surrounding normal cells, it significantly enhances the killing effect of the magnesium alloy on residual tumor tissue. Moreover, the magnesium alloy degrades slowly, making it suitable as an adjunct therapy material after tumor surgical resection, and it shows great potential in continuously inhibiting local tumor recurrence.

[0051] To further illustrate the present invention, the following examples provide a detailed description. All experimental materials used in the following examples are commercially available products. Specifically, the magnesium alloy body was purchased from Suzhou Jingjun Technology Co., Ltd., and the magnesium alloy element mass ratio was Mg:Zn:Ca (97.7:2.0:0.3); the mouse breast cancer cells were provided by Shanghai Fuheng Biotechnology Co., Ltd.

[0052] Example 1

[0053] This embodiment provides a surface-modified magnesium alloy, in which magnesium peroxide is generated in situ on the surface of the magnesium alloy, and further poly-L-arginine hydrochloride is loaded using bovine serum albumin. The specific preparation method is as follows:

[0054] (1) Immerse the magnesium alloy body (referred to as "MgA") in a saturated sodium bicarbonate solution for 12 hours and then remove the magnesium alloy body a.

[0055] (2) The magnesium alloy body a described in step (1) is calcined in a muffle furnace at 500°C for 3 hours to obtain magnesium alloy body b.

[0056] (3) The magnesium alloy body b described in step (2) is immersed in hydrogen peroxide solution at room temperature for 12 hours to obtain a magnesium alloy body with magnesium peroxide grown on the surface (hereinafter referred to as "MM");

[0057] (4) Mix the MM described in step (3) with a neutral 1.6 g / L bovine serum albumin buffer solution at room temperature and react for 12 h to obtain a magnesium alloy body (MMB) loaded with bovine serum albumin after surface growth of magnesium peroxide.

[0058] (5) Mix the MMB mentioned in step (4) with a neutral pH 0.6 g / L poly-L-arginine salt buffer solution and react for 12 h to obtain a magnesium alloy body (MMBP) with surface-grown magnesium peroxide, loaded with bovine serum albumin and finally adsorbed with poly-L-arginine hydrochloride, which is the final surface-modified magnesium alloy.

[0059] Scanning electron microscopy was performed on the aforementioned MgA, MM, MMB, and MMBP, and the results are as follows: Figure 1As shown, the surfaces of MM, MMB, and MMBP are significantly rougher than those of MgA, indicating that the surface of the magnesium alloy body is significantly modified.

[0060] X-ray diffraction tests were performed on MMBP, and the results are as follows: Figure 2 As shown, the X-ray diffraction pattern of MMBP shows diffraction peaks of magnesium peroxide at 37.1° and 53.8° (JCPDS card number 19-0771), indicating that magnesium peroxide was successfully grown in situ on the surface of the obtained magnesium alloy.

[0061] Thermogravimetric analysis was performed on MgA, MM, MMB, and MMBP as described above, and the results are as follows: Figure 3 As shown, MM, MMB, and MMBP all exhibit significant weight loss compared to MgA, with the weight loss of MMBP, MMB, and MM gradually increasing. This indicates that, based on the in-situ growth of magnesium peroxide on the magnesium alloy surface, bovine serum albumin and poly-L-arginine hydrochloride were successfully loaded, proving the successful synthesis of surface-modified magnesium alloy MMBP.

[0062] Tumor cell killing effect test

[0063] Mouse breast cancer cells were seeded into 96-well plates and incubated for 24 h. Then, MgA, MM, and MMBP (diameter D = 0.5 mm, length L = 6 mm) were added to the 96-well plates containing 1640 medium solution at pH 6.5, and the materials and cells were co-incubated for 12 h. An alternating magnetic field (AMF) (magnetic field strength: H) was then applied. appl ×f appl =0.9×10 8 A·m·- 1 ·s -1 The function of AMF (among others) is as follows: AMF group (control group) with only alternating magnetic field applied (containing only cells and 1640 medium solution at pH 6.5); MgA group with MgA added to the wells of the Control group; MM group with MM added to the wells of the Control group; and MMBP group with MMBP added to the wells of the Control group. AMF is applied for 6 minutes. Finally, CCK-8 is added to the wells according to the kit instructions, and cell viability is detected after co-incubation with the materials.

[0064] In addition, in this invention, mouse breast cancer cells were seeded in 96-well plates and incubated for 24 hours. Then, MgA, MM, and MMBP (diameter D = 0.5 mm, length L = 6 mm) were added to the 96-well plates containing 1640 medium solution at pH 6.5, and the materials and cells were co-incubated for 12 hours. An alternating magnetic field (AMF) (magnetic field strength: H) was not applied. appl ×f appl =0.9×10 8 A·m·- 1 ·s -1 The function of the AMF (Ampere-Ampere-Fertilizer) is as follows: The AMF group (without an alternating magnetic field, serving as the control group) contains only cells and 1640 medium solution at pH 6.5 in the wells. The MgA group has MgA added to the wells, the MM group has MM added to the wells, and the MMBP group has MMBP added to the wells. Finally, CCK-8 is added to the wells according to the kit instructions, and cell viability after co-incubation with the materials is detected.

[0065] Test results are as follows Figure 4 As shown, without the application of an alternating magnetic field, the magnesium alloy alone (MgA group) caused partial cell death by generating a large amount of hydrogen gas under acidic conditions. Furthermore, when the magnesium alloy was modified with a magnesium peroxide coating and loaded with drugs (MMBP group), the cell death rate increased further through combined treatment with hydrogen and nitric oxide. However, when an alternating magnetic field was applied, the cell death rates in the MgA, MM, and MMBP groups all increased significantly under the combined effects of magnetothermal therapy and gas therapy. In particular, the MMBP+AMF group (the final treatment group) showed a cell survival rate of less than 20%, indicating that the surface-modified magnesium alloy has excellent killing effects on tumor cells.

[0066] Example 2

[0067] This embodiment provides a magnesium alloy with a zinc oxide coating grown on its surface, and the specific preparation method is as follows:

[0068] (1) The magnesium alloy body was immersed in polyvinylpyrrolidone solution for 2 hours for deposition and adsorption;

[0069] (2) Immerse the product from step (1) in an aqueous solution of zinc acetate and mix it in a shaker for 4 hours;

[0070] (3) Add 3 mL of 30% hydrogen peroxide solution to the solution in step (2);

[0071] (4) Place the product from step (3) on a heating plate at 300°C and heat for 10 minutes to obtain a magnesium alloy with a zinc oxide coating grown on its surface.

[0072] Scanning electron microscopy and X-ray energy dispersive spectroscopy were performed on the magnesium alloy with a zinc oxide coating grown on its surface obtained in Example 2. The results are as follows: Figure 5 and Figure 6 As shown, the surface of the magnesium alloy rod in the scanning electron microscope image becomes rough, indicating that a coating is attached; and the X-ray energy dispersive spectroscopy shows that a large amount of zinc element is uniformly distributed on the surface of the magnesium alloy, proving the feasibility of zinc peroxide coating modification on the surface of the magnesium alloy.

[0073] The above description of the disclosed embodiments enables those skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the invention. Therefore, the invention is not to be limited to the embodiments shown herein, but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. A magnesium alloy, characterized in that, Includes a magnesium alloy body and a peroxide coating covering the surface of the magnesium alloy body; The peroxide coating surface is adsorbed with a protein carrier, and the protein carrier surface is loaded with a NO donor; The magnesium alloy body is composed of the elements Mg, Zn and Ca, wherein the mass ratio of Mg, Zn and Ca is 97.7:2.0:0.3; The peroxide coating includes any one or more of magnesium peroxide coating, zinc peroxide coating, calcium peroxide coating, or strontium peroxide coating; The protein carrier is selected from any one or more of bovine serum albumin, human serum albumin, rabbit serum albumin, or ovalbumin; The NO donor is selected from any one or more of poly-L-arginine hydrochloride, poly-L-arginine, or L-arginine.

2. A method for preparing a magnesium alloy as described in claim 1, characterized in that, Includes the following steps: A magnesium alloy substrate coated with an oxide layer is mixed with a buffer solution of a protein carrier and reacted. The resulting product is then mixed with a buffer solution of a NO donor and reacted to obtain the magnesium alloy.

3. The preparation method according to claim 2, characterized in that, The buffer solutions for the protein carrier and the NO donor are neutral in pH.

4. The preparation method according to claim 2, characterized in that, The magnesium alloy body with an oxide coating on its surface is prepared by in-situ growth or surface deposition.

5. A metal implant that inhibits tumor growth or local tumor recurrence, characterized in that, This includes the magnesium alloy according to claim 1 or the magnesium alloy prepared by the preparation method according to any one of claims 2 to 4.

6. The metal implant according to claim 5, characterized in that, The metal implant is placed in the tumor cell wound after surgery, and an alternating magnetic field is applied to stimulate it. The strength of the alternating magnetic field is 0.1 × 10⁻⁶. 8 ~0.9×10 8 A·m -1 ·s -1 .

Images